Adult ADHD (Attention-deficit hyperactivity disorder ). Disturbance of activity and attention
Conditions
Interventions
Intervention 1: Therapeutic dosage of Memantine 10 mg is prescribed a tablet daily for the first week (one tablet in the night at 10
00 o'clock, and 2 tablets are daily prescribed in the second week (one tablet in the morning at 8
00 o'clock, one tablet at 10
00 o'clock). Intervention 2: Placebo is prescribed a tablet daily for the first week (one tablet in the night at 10
00 o'clock).
Treatment - Drugs
Placebo
Therapeutic dosage of Memantine 10 mg is prescribed a tablet daily for the first week (one tablet in the night at 10
Placebo is prescribed a tablet daily for the first week (one tablet in the night at 10
Sponsors
Kurdistan University of Medical science
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: receiving DSM-IV-TR diagnostic criteria for ADHD; the age range of 18 to 45 years old; not using any psychiatric drugs at least 2 weeks before the research. Exclusion criteria: having mental retardation; having any psychiatric disorders except Oppositional Defiant disorder; allergic history to Memantine; having serious disorder like heart disease; uncontrolled Seizure disorder; individuals with Systolic blood pressure above 125 mmHg or resting pulse under 60 or having above 115 beats per minute: Pregnant and lactating women
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects. Timepoint: third and sixth weeks after intervention. Method of measurement: checklist of side effects.;Efficacy in more than 50% of reduction in ADHD diagnostic rating scale. Timepoint: six weeks after treatment. Method of measurement: Parent interview. | — |
Primary
| Measure | Time frame |
|---|---|
| Improvement in hyperactivity symptome. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conners' Adult ADHD Rating Scales–Self-Report.;Improvement in Impulsivity symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conners' Adult ADHD Rating Scales–Self-Report.;Improvement in Attention-deficit symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conners' Adult ADHD Rating Scales–Self-Report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoleiman Mohammadzadeh
Kurdistan University of Medical Sciences
Outcome results
None listed